Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Phase 1
- Conditions
- Non-small Cell Lung CancerFirst-line Treatment
- Interventions
- Biological: CIK cellBiological: Sintilimab Injection
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2020-07-07
- Target Recruit Count
- 30
- Registration Number
- NCT03987867
- Locations
- π¨π³
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2020-07-08
- Target Recruit Count
- 1213
- Registration Number
- NCT03983096
- Locations
- π¨π³
Jin Zhang, Tianjin, China
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 198
- Registration Number
- NCT03950154
- Locations
- π¨π³
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2019-06-14
- Target Recruit Count
- 146
- Registration Number
- NCT03944980
- Locations
- π¨π³
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients
Phase 2
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Biological: Sintilimab
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2019-03-19
- Target Recruit Count
- 43
- Registration Number
- NCT03874000
- Locations
- π¨π³
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer
Not Applicable
Completed
- Conditions
- The Clinical Application Guide of Conebeam Breast CT
- Interventions
- Device: CBBCT
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 800
- Registration Number
- NCT03861221
- Locations
- π¨π³
Tianjin Medical University Cancer Institute And Hospital, Tianjin, Tianjin, China
Outcome of Resection for Colorectal Cancer
Not Applicable
- Conditions
- Laparoscopy
- Interventions
- Procedure: minimally invasive surgery
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2019-02-12
- Target Recruit Count
- 1300
- Registration Number
- NCT03837782
- Locations
- π¨π³
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
The MDA Test to Differentiate of Benign and Malignant Pulmonary Nodules
- Conditions
- Pulmonary Nodule, Solitary
- Interventions
- Diagnostic Test: FISH
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2019-01-02
- Target Recruit Count
- 200
- Registration Number
- NCT03790735
- Locations
- π¨π³
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection
Phase 3
- Conditions
- CholangiocarcinomaGall Bladder Carcinoma
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2018-12-19
- Target Recruit Count
- 460
- Registration Number
- NCT03779035
- Locations
- π¨π³
Tianjin Medical University Cancer Insititute and Hospital, Tianjin, Tianjin, China
A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization
Phase 2
- Conditions
- HPVCervical Intraepithelial Neoplasia
- Interventions
- Biological: Composite Gel Containing Black RaspberryBiological: placebo
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Target Recruit Count
- 78
- Registration Number
- NCT03745846
Β© Copyright 2025. All Rights Reserved by MedPath